Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase^®.

ABSTRACT:

Background

Current evidence on the safety of calcitonin gene-related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive information. By querying VigiBase^®, the World Health Organization global pharmacovigilance database, this study aimed to detect differences in the reporting frequency between CGRP-A and triptans in relation to pregnancy.

Methods

Disproportionality analyses on de-duplicated safety reports collected in VigiBase^® as of 31.05.2023 reporting exposure to CGRP-A in pregnancy with or without pregnancy outcomes. A Reporting Odds Ratio (ROR) with a 95% confidence interval (CI) was used as a measure of disproportionality and the threshold for the detectio

SUBMITTER: Noseda R 

PROVIDER: S-EPMC10799383 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature